We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bio-Rad and Axis-Shield Sign Agreement for Anti-CCP

By HospiMedica staff writers
Posted on 26 Jan 2007
Bio-Rad Laboratories, Inc. More...
(Hercules, CA, USA), a manufacturer and distributor of life science research and clinical diagnostics products and Axis-Shield (Dundee, Scotland), an in vitro diagnostics company, have signed an agreement that gives Bio-Rad access to Axis-Shield's test for the early detection of rheumatoid arthritis (RA).

The new assay will run on Bio-Rad's BioPlex 2200 system and tests for anti-CCP (anti-cyclic citrullinated peptide antibodies). The anti-CCP assay is a significant recent development in the early diagnosis of rheumatoid arthritis, facilitating improved management of this widespread and debilitating condition. The anti-CCP assay is regarded by many experts as the most significant recent development in the early diagnosis of RA, facilitating improved management of this widespread and debilitating condition, affecting over 2 million people in the United States alone.

Svein Lien, Axis-Shield's CEO, commented: "We are very pleased that our important patented assay for anti-CCP will be added to the menu of this versatile platform. We have a history of successful collaboration with Bio-Rad, which is a highly respected and pioneering organization in life sciences and a major player in human diagnostic testing, and believe the BioPlex system will add an extra dimension to anti-CCP marketing.”

"The ability to develop and launch an anti-CCP test as part of a rheumatoid arthritis panel will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system,” said John Goetz, Bio-Rad vice president and group manager of Clinical Diagnostics. "As the first and only fully automated and random access multiplex testing platform, the BioPlex 2200 system is ideally suited as a platform for multimarker autoimmune testing that includes rheumatoid arthritis.”

Axis-Shield is a global manufacturer of in vitro diagnostic kits with a focus on new markers in cardiovascular, rheumatoid, infectious, and alcohol-related diseases, diabetes, dementia, and near-patient testing to facilitate improved patient management.

Bio-Rad Laboratories manufactures and distributes a broad range of products for the life science research and clinical diagnostics markets.



Related Links:
Bio-Rad Laboratories
Axis-Shield

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Immobilization System
Cranial 4Pi Immobilization
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.